Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
UBS
Colorcon
Dow
Fuji
Accenture
AstraZeneca
Boehringer Ingelheim
US Department of Justice
Mallinckrodt

Generated: October 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,458,374

« Back to Dashboard

Which drugs does patent 7,458,374 protect, and when does it expire?


Patent 7,458,374 protects ADASUVE and is included in one NDA.

This patent has one hundred and ninety-five patent family members in nineteen countries.

Summary for Patent: 7,458,374

Title:Method and apparatus for vaporizing a compound
Abstract: Disclosed is a method and device for rapid heating of a coated substance which preferably includes a drug to vaporized for inhalation therapy. A device in accordance with the present invention preferably includes a substrate which has an interior surface surrounding an interior region and an exterior surface upon which the coated substance is to be adhered. Though the substrate is preferably metallic, it does not need to be. A combustible element is placed in the interior region of the rigid substrate and an igniter is connected to the combustible element. The igniter is for initiating oxidation of the combustible element. Preferably, the coated substance is vaporized inside of a housing to allow the vaporized drug to aerosolize and be inhaled by a user.
Inventor(s): Hale; Ron L. (Woodside, CA), Song; Soonho (Hillsborough, CA), Quintana; Reynaldo J. (Redwood City, CA), Zaffaroni; Alejandro C. (Atherton, CA), Rabinowitz; Joshua D. (Princeton, NJ)
Assignee: Alexza Pharmaceuticals, Inc. (Mountain View, CA)
Application Number:10/146,086
Patent Claim Types:
see list of patent claims
Composition; Device; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Galen Uk
ADASUVE
loxapine
POWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,458,374

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,078,019Delivery of drug esters through an inhalation route► Subscribe
7,008,616Delivery of stimulants through an inhalation route► Subscribe
7,470,421Delivery of diazepam through an inhalation route► Subscribe
7,078,016Delivery of caffeine through an inhalation route► Subscribe
6,737,042 Delivery of drug esters through an inhalation route► Subscribe
7,465,437Delivery of anti-migraine compounds through an inhalation route► Subscribe
7,524,484Delivery of diphenhydramine through an inhalation route► Subscribe
7,014,840Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route► Subscribe
9,687,487Aerosol forming device for use in inhalation therapy► Subscribe
6,803,031 Delivery of erectile dysfunction drugs through an inhalation route► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,458,374

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria365548► Subscribe
Austria401063► Subscribe
Austria401064► Subscribe
Austria404173► Subscribe
Austria404184► Subscribe
Austria406878► Subscribe
Austria415155► Subscribe
Austria418330► Subscribe
Austria418971► Subscribe
Austria425746► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Federal Trade Commission
Citi
Cipla
Deloitte
Julphar
Cerilliant
Boehringer Ingelheim
Express Scripts
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot